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The signal transduction field has recently seen a surge of interest in cascade scaffolding proteins.  
One of these, the Kinase Suppressor of Ras (KSR), has received a great deal of attention as a 
scaffold for the Ras/ERK signaling pathway.  KSR interacts with both MEK and ERK, and 
possibly binds to Raf-1 as well.  Very little is known about the regulation of KSR; however, it 
has been determined that membrane association is essential for its function in signal 
augmentation.  KSR shares a high degree of sequence homology to Raf-1, including an almost 
identical phosphatidic acid binding region (PABR).  Previous work in the Romero lab has 
determined the direct interaction of Raf-1 with phosphatidic acid is critical for its membrane 
recruitment.  The PABR is a 35 amino acid sequence consisting of a poly-basic motif (PBM) 
flanked by two hydrophobic regions.  Neutralization of the two arginine residues in the PBM 
abrogates the binding of Raf-1 to phosphatidic acid (PA), and consequently disrupts its 
membrane association.  This thesis examines lipid-binding properties of the PABR and their 
potential role in the traffic and function of KSR.  Using peptides corresponding to the PABR and 
tryptophan fluorescence spectroscopy, the data presented in the first section demonstrate that PA 
induces a blue-shift in the tryptophan emission spectra of WT KSR PABR, and this shift is 
specific for PA.  The second section explores the cellular consequence of KSR PABR mutation.  
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A KSR protein lacking the arginine residues in the PBM expressed in HIRcB fibroblasts retains 
its membrane-binding ability, but inhibits MEK and ERK phosphorylation in a dominant 
negative fashion.  The data presented here support the conclusion that, although an intact PABR 
may not be essential for the membrane localization of KSR, it is essential for proper coupling of 
the pathway. 
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FOREWARD 
Once upon a time, when imagination soared and possibilities were endless, I dreamed of what I 
would be “when I grew up.”  I can remember intentions to become everything from a disc jockey 
to a commercial pilot to a concert pianist.  Admittedly, I can also recall a great deal of indulgent 
smiling and nodding from my family during this time. 
The years passed, and I settled on a career in science.  I freely confess I initially pursued biology 
courses as a means to an end – that end being medical school.  Then one day, during my AP 
Biology class, I had an epiphany: I found the phrase “by an unknown mechanism” for the first 
time in a textbook.  I was stunned, for in my naiveté, I had assumed scientists already had all the 
answers.  At the same time, however, I was profoundly confused – how could modern science 
and medicine hope to treat what was not yet completely understood?  And suddenly, that simple 
phrase in my textbook became a call to arms. 
There have been many who have questioned this decision, wondering why I did not become a 
musician.  Indeed, I have devoted a tremendous portion of my life to my musical pursuits, and 
can therefore understand the perception that music is my greatest passion.  Friedrich Nietzsche 
said, “Without music life would be a mistake,” and I could not agree more; however, I would 
like to take this opportunity to correct a misconception.  My greatest passion is, in fact, learning.  
And where better to indulge my love of learning than the scientific field?  A place where each 
day brings a new paper, a new piece of data, or a new outlook into the mechanics of what 
Douglas Adams called “Life, the universe, and everything.”  I truly could not imagine myself 
doing anything else, and it is my fervent hope that someday, the girl who was riveted by the 
unknown once upon a time might learn just enough to make a difference. 
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Whoso neglects learning in his youth, 
    Loses the past and is dead for the future. 
- Euripides, Phrixus
 
 
 
When we remember we are all mad, the mysteries 
     disappear and life stands explained. 
- Mark Twain 
 
 
 
…To strive, to seek, to find, and not to yield. 
- Alfred Lloyd Tennyson, “Ulysses” 
 
 
 
           When you get to the end of your rope,  
      tie a knot and hang on. 
- Franklin D. Roosevelt 
 
 
 
Nothing shocks me.  I’m a scientist. 
      - Indiana Jones 
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 1. Introduction 
1.1. MAPK Signaling 
Mitogen-activated protein kinases, or MAPK’s, are a ubiquitous class of signaling proteins 
implicated in a number of cellular functions, such as proliferation, differentiation, and apoptosis.  
Three MAPK cascades have been identified to date: the extracellular-signal regulated kinases 
(ERK’s), and the two stress-activated protein kinases (SAPK’s) c-Jun N-terminal kinase (JNK) 
and p38.  These three pathways, although they differ in activation and function, share a common 
structural thread.  Each signaling cascade is comprised of three sequentially activated kinases: a 
MAPK kinase kinase (MAPK3K), a MAPK kinase (MAPK2K), and the ultimate MAPK.  When 
the MAP3K is activated, it phosphorylates the MAP2K, which in turn phosphorylates and 
activates the MAPK [1].   
The SAPK JNK is activated in response to various cellular stresses, cytokines, growth factors, 
and ceramides, and is functionally implicated in proliferation, differentiation, and apoptosis [2].  
The JNK’s get their name from their phosphorylation of c-Jun, a DNA-binding protein 
component of the AP-1 transcription complex.  AP-1 regulates the transcription of many genes 
involved in the cell stress response [1].  The p38 MAPK is activated by many of the same stimuli 
as JNK, including stress, cytokines, growth factors, and TGF-β.  In addition to proliferation, 
differentiation, and apoptosis, p38 has also been implicated in development and inflammation 
[1].  p38 plays a critical role in the cell response to various stresses such as radiation, high 
osmolarity, and heat shock [2].  As there is a great deal of functional overlap between p38 and 
JNK, they share a number of the same upstream activators.  These are summarized in Figure 1.  
Shared kinases include the class of MAP3K’s known as mixed lineage kinases (MLK), apoptosis 
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Figure 1 - JNK, p38, and ERK1/2 MAPK Cascades 
 
There are three main families of MAPK proteins, the SAPK’s JNK and p38, and the ERK’s.  All 
MAPK cascades consist of three kinase modules: a MAP3K, which phosphorylates and activates 
a MAP2K, which in turn phosphorylates the MAPK.  JNK’s and p38 are implicated in the 
cellular response to various stresses, while the ERK’s regulate growth and differentiation. 
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 signaling kinase (ASK), and TGF-activated kinase (TAK).  MAP2K’s for these pathways include 
MKK3, 4, and 6 for p38, and MKK4 and 7 for JNK [2]. 
ERK1 and ERK2 are widely expressed signaling molecules which are involved in cell growth, 
differentiation, and development.  Targets for ERK’s include transcription factors such as ELK1 
and STAT proteins [2].  In addition to basic phosphorylation of targets, duration of ERK 
activation has been implicated in pathway consequence.  Nerve growth factor (NGF), fibroblast 
growth factor (FGF), and epidermal growth factor (EGF) all stimulate the rapid activation of 
ERK in PC-12 cells.  The EGF response is transient, while FGF- and NGF-mediated MAPK 
activation is sustained.  This protracted phosphorylation of ERK is essential for NGF- and FGF- 
stimulated differentiation [3].  ERK1/2 are activated by the dual-specificity kinases MEK1 and 
MEK2.  MEK1/2, in turn, are phosphorylated by the MAP3K family of Raf proteins, which can 
be activated by the proto-oncogene Ras [1]. 
1.2. Phosphatidic acid in MAPK signaling 
The first evidence that phosphatidic acid (PA) played a role in ERK signaling came in 1996, 
when the PA-binding region (PABR) of Raf-1 was first described [4].  Previous work with the 
MAP3K Raf-1 had demonstrated its interaction with phosphatidylserine (PS) through its N-
terminal cysteine-rich region [5].  Further lipid binding analysis of Raf-1 determined that the 
full-length protein also bound to PA.  Deletion experiments determined the minimum region for 
PA binding is amino acid 389 through 423, located in the C-terminal kinase region.  The PABR 
is characterized by hydrophobic residues flanking a poly-basic motif (PBM), which consists of 
two arginine residues (R398, R401).  Substitution of these basic residues for neutral alanines 
results in a mutant unable to interact with PA [6, 7], indicating that there is an electrostatic 
component to this association.  Raf-1 PA binding is not mediated exclusively by electrostatic 
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 interactions, however.  Increasing concentrations of salt do not disrupt the protein lipid 
interaction, as would be expected if association was regulated by charge alone.  Lipid binding of 
the PABR is specific for PA; binding to other acidic lipids was negligible, as was binding to 
phosphatidyl alcohols [4].  In addition, using surface plasmon resonance (SPR), Rapp and 
colleagues have reported Raf-1 to bind to mixed composition liposomes containing phosphatidic 
acid, phosphatidylcholine, phosphatidylethanolamine, sphingomyelin, and cholesterol with an 
apparent KD of 0.5nM [8].  Hence the PA-PABR interaction is specific, and requires not only 
electrostatic associations with the PBM but hydrophobic interaction with the lipid acyl chains as 
well. 
Further characterization of this protein-lipid interaction revealed that PA is required for the 
recruitment of Raf-1 to the plasma membrane, a critical step in its activation by Ras [4, 7, 9, 10].  
There are three mechanisms of PA synthesis in cells: 1) phosphorylation of diacylglycerol 
(DAG) by DAG kinase, 2) acylation of lyso-PA by acyl transferases, and 3) hydrolysis of 
phosphatidylcholine by phospholipase D (PLD) [9].  The initial work characterizing Raf-1 
translocation implicated PLD as the source of PA.  Primary short chain alcohols compete with 
water in the transphosphatidylation reaction catalyzed by PLD, creating a phosphatidyl alcohol 
instead of an acid.  Incubation of cells with ethanol resulted in a decrease in Raf-1 present in the 
membrane fraction [4].  Further studies corroborated these data using Brefeldin A (BFA), which 
inhibits PLD activity through interference with its activator, ARF [10].   
Two mammalian isoforms of PLD have been identified, PLD1 and PLD2 [9].  Transfection of 
cells with a PLD1 dominant negative construct had no effect, while PLD2 abrogated insulin-
induced ERK phosphorylation, as well as Raf-1 membrane association [10].  Mutations of the 
arginine residues in the PBM interfere with Raf-1 membrane binding, as well as generate a 
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 dominant negative mutant.  Raf-1 R398A has a reduced affinity for PA in vitro, and inhibits 
insulin-induced activation of ERK.  Furthermore, expression of the Raf-1 PABR fused to green 
fluorescent protein (GFP) decreases ERK phosphorylation in response to agonist, while a GFP-
PABR PBM mutant had no effect [7].  Taken together, these data indicate that agonist-induced 
Raf-1 membrane translocation is mediated by a direct interaction with PLD2-generated PA. 
Recent work by Ghosh and colleagues has also determined a physiological significance for the 
PABR.  Mutation of the tetrapeptide Raf-1 PBM (residues 398-401) to alanines resulted in a Raf-
1 incapable of PA interaction.  Zebrafish embryos injected with RNA encoding this PBM mutant 
exhibit bent trunk and tail structures, a developmental defect in posterior axis formation.  In situ 
hybridization of the no tail gene, which functions downstream of Raf-1, reveals this anatomical 
deficiency is due to aberrant signaling through Raf-1 [6].  Consequently, binding of PA is critical 
for Raf-1 function in embryonic development. 
1.3. Endocytosis in MAPK signaling 
Endocytosis of cell surface receptors has long been considered a means by which signaling can 
be downregulated or terminated.  Recent work has demonstrated, however, that internalization of 
receptors does not lead to signal cessation.  Rather, receptor endocytosis is emerging as a critical 
step in the signaling process.  Interference with endocytosis results in a decrease in ERK 
activation, whether accomplished by cholesterol depletion with cyclodextrin, cytochalasin D 
treatment [11], or dynamin negative mutants [12].  Cells defective in clathrin-mediated 
endocytosis exhibit a reduction in ERK phosphorylation in response to EGF [13].  Additional 
studies have demonstrated that ERK phosphorylation does not necessarily require internalization 
of the activated receptor.  In Cos cells, G-protein coupled β2A and α2A adrenergic receptors 
(AR) both activate ERK, and this activation is sensitive to inhibitors of clathrin-mediated 
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 endocytosis.  Of these two AR’s, only the β2A receptor is internalized, while the α2A receptor 
remains at the plasma membrane.  Activation of both of these receptors, however, results in the 
transactivation of the EGF receptor, and its subsequent internalization [14].  Hence, although 
endocytosis of receptors appears to be required for activation of the ERK cascade, the 
internalization event is not necessarily specific for the activated receptor.  
Insight into this endocytic requirement for signaling came with the discovery of Ras/ERK 
signaling components on the surface of early endosomes following insulin stimulation.  These 
“signaling endosomes” contain activated Ras, Raf-1, MEK, and ERK, as well as the insulin 
receptor [7, 15].  These endocytic vesicles also contain PLD2 on their surface, and are enriched 
in phosphatidic acid (PA) [15] and cholesterol [11].  The lipid composition of the endosome also 
changes as a function of time.  Maximum levels of PA are reached between five and fifteen 
minutes after stimulation, coincident with peak association of Raf-1 [15].  Mutation of the Raf-1 
PBM (R398A) renders it incapable of associating with the endosomal compartment.  Of 
particular interest, overexpression of a Raf-1 PABR GFP fusion abrogated the endosomal 
association of Raf-1 [7], presumably by binding to PA and preventing Raf-1 access.  This data 
suggests that endosomal lipid composition plays an important role in signal coordination. 
1.4. Scaffolds in MAPK signaling 
1.4.1. Scaffolding in yeast 
The Saccharomyces cerevisiae ste5 gene product represents the first recognized MAPK scaffold.  
Ste5p was identified by a genetic screen for perturbations in hormone-regulated mating [16].  
The yeast reproductive process is initiated by peptide mating hormones, which in turn activate a 
G-protein coupled MAPK cascade.  This particular MAPK pathway consists of the MAP3K 
kinase, Ste20p, MAP3K Ste11p, MAP2K Ste7p, and MAPK’s Fus3p and Kss1p [17].  
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 Overexpression of Ste5p enhanced activation of Fus3p, while deletion experiments confirmed its 
positive regulation of the mating pathway [18, 19].   
Insight into Ste5p’s scaffolding function came about through the demonstration of its selective 
interaction with all four of the mating pathway kinases through separable binding sites [18, 20, 
21].  Additionally, binding to Ste5p was determined to be the rate limiting step for activation of 
Fus3p [18].  The most compelling data for Ste5p function as a scaffold, however, was obtained 
through sedimentation experiments.  The highest specific activity of Fus3p is observed when it is 
associated with a large multi-protein complex consisting of all the MAPK pathway kinases and 
Ste5p.  Deletion of Ste5p abrogates the association of Fus3p with this complex, and consequently 
reduces its activity [22]. 
A role for Ste5p in mediating MAPK specificity has also been suggested.  The MAP3K Ste11p 
has been implicated in multiple cellular responses, including filamentous growth, mating, and the 
high-osmolarity glycerol (HOG) response [23].  Each of these three pathways employs a distinct 
MAPK: Kss1p, Fus3p, and Hog1p, respectively [24].  Specificity was explored using protein 
fusions of Ste11p with different pathway components.  Ste11p fused to Ste5p retained the ability 
to complement Δste11 yeast, while linking to Pbs2, a putative scaffold in the HOG response, 
cannot complement these deletion animals [25].  Thus, tethering function of Ste5p in yeast is not 
only essential for coupling of mating MAPK signaling, but may mediate pathway specificity and 
cellular response as well. 
1.4.2. SAPK scaffolding 
Scaffolds identified for mammalian SAPK scaffolding include β-arrestin-2, CrkII, Filamin, 
IKAP, JIP1-4, MKPX, POSH, and SKRP1 [26].  The best characterized of these is the family of 
proteins known as JNK interacting proteins, or JIP’s.  There have been four JIP’s identified, all 
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 encoded by distinct genes.  Based on their sequence similarities, JIP’s can be divided into two 
classes: JIP1/JIP2, which contain a C-terminal SH3 and PTB domain, and JIP3/JIP4, which 
consist of an extended coiled-coil domain [26].  Although mammalian JIP’s share no sequence 
homology with yeast Ste5p, these two proteins are the most functionally equivalent scaffolds 
identified to date.  As discussed above, Ste5p scaffolds all of the kinases of the mating MAPK 
pathway.  JIP’s also interact with complete three-kinase JNK modules, and in doing so not only 
augment signaling, but protect from aberrant JNK activation [27].  JIP1 and JIP2, for example, 
have been shown to bind to MAPK JNK, MAP2K MKK7, and various MAP3K mixed lineage 
kinases (MLK) [26].  It is also intriguing that the MAPK phosphatase MKP7 can also be found 
associated with both JIP1 and JIP2.  Association of MKP7 to JIP1 scaffolds has been shown to 
inhibit JNK activation [28].  Hence, in addition to facilitating signaling through complex 
assembly, JIP scaffolding complexes also contain a mechanism by which signaling can be 
inhibited.   
The physiological relevance of JIP proteins remains unclear.  JIP3 null mice, for example, die 
soon after birth due to severe defects in brain development [29].  There have been three separate 
reports of JIP1-deficient mice.  One group reported deletion of JIP1 to be embryonic lethal [30], 
while the most recent description of JIP1 knockouts reports the mice to be healthy and viable, 
but defective in neuron recovery following ischemic insult [31].  Yet another study confirms JIP 
null mice to be viable but defective in neuronal JNK regulation [32].  Additional studies will be 
required to more fully discern the physiological role of JIP scaffolds. 
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 1.4.3. ERK1/2 scaffolds 
Determination of a bona fide scaffolding protein for the ERK1/2 signal cascade has proven more 
complex than for the other MAPK pathways.  Scaffolding function has been attributed to a 
number of proteins, however, and these include MP1, MORG-1, β-arrestin, CNK, MEKK-1, 
RKIP, and KSR [26] (Figure 2). 
1.4.3.1. MP1 and MORG-1 
The first of these, MEK partner 1 (MP1), confers a level of specificity in ERK signaling, in that 
it binds only ERK1 and MEK1 [33].  MP1 has been demonstrated to localize MEK1 and ERK1 
selectively to the surface of late endosomes and lysosomes.  This membrane interaction is 
mediated by p14, a small protein on the lysosomal surface [34, 35].  By mistargeting p14 to the 
plasma membrane, MP1 localization is likewise misdirected [35], and siRNA knockdown of p14 
results in MP1 being relocated to the cytosol.  Furthermore, cells lacking p14 or MP1 are 
defective in ERK1/2 phosphorylation, with ERK1 being more severely inhibited than ERK2 
[34].  MP1 association with ERK1 decreases in response to agonist or activated Ras, while levels 
of bound MEK1 do not change [36].  Recent work has also demonstrated that MP1 may mediate 
agonist specificity in MAPK phosphorylation.  Pak-1-dependent phosphorylation of ERK 
requires MP1 and p14, while PDGF stimulation is independent of the scaffold [37].  
Furthermore, the latest report concerning MP1 has shown it to dimerize in cells [36], but the 
physiological role of this dimerization has not been explored.  Hence, as a scaffold, MP1 is not 
only required for proper activation of the pathway, but for localizing it to the proper intracellular 
compartment as well. 
MP1 is a very small protein (14.5 kiloDaltons), which has raised speculation that it is not large 
enough to accommodate MEK1 and ERK1 as a scaffold.  The identification of mitogen-activated 
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 protein kinase organizer 1 (MORG-1) may serve to allay some of these concerns [38].  MORG-1 
and MP1 have similar tissue expression patterns; both are ubiquitously expressed.  mRNA 
transcripts for both have been isolated in heart, brain, lung, liver, muscle, kidney, spleen and 
testis, only differing slightly in relative abundance in several tissues [33, 38].  Although the only 
binding partners identified for MP1 to date are p14, MEK1 and ERK1, MORG-1 has been shown 
to interact with MP1, Raf-1, B-Raf, MEK1/2, and ERK1/2.  Moreover, siRNA knockdown of 
MORG-1 reveals it to be an essential component of serum stimulated ERK phosphorylation, but 
not necessary for EGF-dependent ERK activation [38].  Intracellular localization patterns of 
MORG-1 have not been determined.  If MORG-1 and MP1 subcellular distributions coincide, it 
is conceivable that these two proteins may work together to couple ERK signaling.  MP1 does 
not bind to Raf-1, but MORG-1 could overcome this deficiency by its interaction with both Raf-
1 and MP1. 
1.4.3.2. RKIP 
The scaffolds discussed to this point have all augmented MAPK signaling.  The discovery of the 
Raf kinase inhibitor protein (RKIP) represents the first inhibitory ERK scaffolding molecule 
[39].  RKIP interacts with Raf-1, MEK, and ERK, but does not bind to Ras.  Although MEK and 
ERK can associate simultaneously with RKIP, the binding sites for MEK and Raf-1 overlap.  
Concurrent occupation of RKIP by MEK and Raf-1 is therefore impossible, and the scaffold 
sequesters the proteins from each other – thereby ultimately inhibiting the activation of ERK.  
Moreover, in order to reverse RKIP-mediated inhibition of ERK phosphorylation, both the MEK 
and Raf-1 binding sites on the scaffold must be eliminated, implying that binding of one is 
sufficient for inhibition [40]. 
10 
  
Figure 2 - ERK1/2 Scaffolding Proteins 
 
ERK scaffolding function has been attributed to a number of proteins.  MP1 (A) is a small 
molecule which selectively binds MEK1 and ERK1, and is tethered to the lysosomal surface by 
p14.  Another putative scaffold, MORG (B), also interacts with MP1, in addition to Raf, MEK, 
and ERK.  It has been suggested that these two proteins synergize to augment ERK 
phosphorylation.  Conversely, RKIP (C) is an inhibitory scaffold.  RKIP binds to MEK and Raf, 
but these binding sites overlap, making concurrent binding impossible.  Thus, RKIP sequesters 
signaling components from activation. 
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 Recently, RKIP has garnered a great deal of attention in oncology, in that it has been identified 
as a metastasis suppressor gene.  Examination of prostate cancer cells determined that degree of 
metastasis corresponded to a progressive loss of RKIP expression [41].  Additionally, inhibition 
of ERK phosphorylation by rituximab, a drug shown to sensitize non-Hodgkin’s lymphoma cells 
to chemotherapeutic drugs and apoptosis, has been shown to be mediated by upregulation of 
RKIP [42]. 
1.5. KSR 
The Kinase Suppressor of Ras (KSR) represents one of the more enigmatic scaffolds identified 
for Ras/ERK signaling to date.  Although KSR is widely accepted as an ERK scaffold, its exact 
role in facilitating this signaling pathway remains elusive. 
1.5.1. Discovery 
KSR was originally isolated in Drosophila melanogaster and C. elegans as a novel suppressor of 
phenotypes caused by overexpression of activated Ras [43-46].  In Drosophila, development of 
R7 photoreceptor cells requires activation of the RAS pathway.  Overexpression of G12V RAS 
leads to the “rough-eye” phenotype, caused by an overproduction of R7 cells [46].  Flies 
examined expressing both activated RAS and KSR, however, maintain a normal phenotype.  
This suggested that KSR antagonized activated RAS, giving rise to its name as a suppressor of 
Ras [43, 46].  
In the case of C. elegans, the let-60 Ras pathway is involved in vulval formation.  Gain of 
function mutations in the pathway lead to the formation of multiple vulvas (MUV), whereas a 
loss of function results in the “vulvaless” phenotype [46].  Overexpression of activated Ras in 
this system leads to the MUV phenotype, but addition of ksr-1 abrogates this effect.  It is 
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 interesting to note that although overexpression of the activated MAP3K in both of these systems 
also results in the “activated phenotype,” addition of ksr-1 has no effect.  Moreover, genetic 
epistasis experiments revealed that ksr-1 appeared to be functioning downstream of Ras, but 
either upstream or in parallel with Raf [44-46]. 
1.5.2. Domain architecture 
KSR is a member of the “Tyrosine-kinase like” class of proteins (TKL), which is a broad class of 
proteins grouped together based on sequence similarity in their kinase domains which all 
members contain.  The TKL group is diverse and contains both serine/threonine and tyrosine 
kinases, but shares high sequence identity to tyrosine kinase domains.  The RAF protein family 
is a small family of highly related members of the TKL group and consists of all Raf isoforms, as 
well as KSR-1 and KSR-2.  To date, KSR-1 homologs have been isolated in C. elegans, 
Drosophila melanogaster and virilis, Mus musculus, and Homo sapiens [43-45].  Quite recently, 
a second ksr has been cloned in C. elegans, and ksr-2a is 35% identical to ksr-1 [47]  KSR-2 has 
also been described in humans, and is predicted to exist in a mouse model as well [48].   
The domain architecture of the Raf protein family is shown in Figure 3. N-terminally, KSR 
contains a 40 residue segment not found in any other protein family (CA1, unique domain). The 
CA1 region is absent in hKSR-1 [43] and hKSR-2 [48].  Proceeding towards the C-terminus, 
KSR contains a proline rich region (CA2), a cysteine rich C1 domain (CA3), and a 
serine/threonine enriched region (CA4).  The most C-terminal portion of the protein is the 
putative kinase domain (CA5), although the functionality of this region is controversial.  All 
known protein kinases have a lysine residue downstream of a glycine-rich region, located in 
subdomain II, one of eleven subdomains conserved in all known kinases.   This lysine 
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 participates in the binding of the α-phosphate of ATP.  KSR contains an arginine at this position 
[43-45].  This region is discussed in detail in a later section (Section 1.5.4.2 – Kinase). 
KSR and Raf are quite similar in sequence. While Raf is lacking the CA1 and CA2 domains and 
KSR lacks the Ras-binding domain, the remainder of the sequence starting with the CA3 domain 
is related. In mice, for example, this stretch shared by Raf-1 and KSR-1 is 28% identical and 
46% similar.  It is in the CA5 kinase domain that we find the most sequence similarity between 
KSR and Raf.  Drosophila RAF and KSR kinase domains are 41% identical and 61% similar 
[43], while in C. elegans, KSR shares 30% identity with lin-45 Raf within the kinase domain, 
and 23% identity overall [44].  The most interesting aspect of this homology is KSR’s possession 
of an almost identical PA- binding region.  As mentioned above, the PABR consists of a PBM 
surrounded by hydrophobic sequences.  This sequence is located between amino acid position 
604-641 in mKSR1, with the essential arginine residues being at position 612 and 615 (Figure 
4A).  It is interesting to note that the PABR sequence is well conserved across species, including 
the recently isolated KSR-2 in C. elegans [47] and human KSR-2 [48], see Table 1.  The role of 
this sequence in KSR function has not been explored.   
1.5.3. Physiological role of KSR 
When examined in an invertebrate physiological context, KSR appears to be absolutely essential 
for Ras-mediated signaling in several species.  In C. elegans, elimination of ksr-1 alone is non-
lethal; animals exhibit minor abnormalities in sex myoblast migration  [44, 45, 49].  siRNA 
knockout of ksr-2 also caused no gross anatomical defects, but these animals were sterile.  This 
sterility was caused by arrest of developing oocytes in the pachytene stage of prophase I.  These 
phenotypes are similar to those observed in animals having a loss-of-function mutation in let-60 
Ras.  Intriguingly, ablation of both ksr-1 and ksr-2 results in a severe Ras-like phenotype and 
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Figure 3 - Domain Architecture of KSR 
 
KSR consists of five conserved regions.  The N-terminal CA1 domain is a region unique to the 
KSR family of proteins.  This region is absent in both human KSR homologues.  Other domains 
include the CA2 proline-rich, CA3 cysteine-rich, and the CA4 serine/threonine-rich regions.  The 
largest domain in KSR is the C-terminal putative kinase domain.  (DmKSR: D. melanogaster 
KSR, CeKSR: C. elegans KSR, mKSR: M. musculus KSR, hKSR: H. sapiens KSR) 
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 subsequent lethality due to a total lack of development of the excretory system.  Individually, 
ksr-1 and ksr-2 are required for separate Ras-mediated processes: sex myoblast migration, and 
excretory and reproductive development, respectively [47].  Together, although there is a degree 
of redundancy in their function, ksr-1 and ksr-2 are apparently essential for Ras-dependent 
signaling in C. elegans.  Likewise, KSR is a requisite component of insulin-induced activation of 
MEK and ERK in Drosophila S2 cells.  siRNA knockout of KSR results in a loss of activity in 
this Ras-mediated pathway [50].  It is not surprising to note that loss of KSR expression in 
Drosophila is embryonic lethal [43], as this is the only species in which a second KSR homolog 
has not been identified.   
In mammals, KSR-1 knockout mice have been generated.  These animals appear grossly normal; 
however, ERK phosphorylation is sufficiently inhibited to hamper tumor cell development and 
block T-cell activation [51].  Targeted disruption of KSR-2 has not yet been examined, but the 
data from the invertebrate knockout experiments suggests that although single knockouts may 
have no overtly deleterious phenotype, ablation of both KSR homologs would be lethal. 
1.5.4. Function 
1.5.4.1. Original theories 
The genetic data, combined with an analysis of the primary structure of KSR as a putative 
kinase, initially led to three possible models for its function.  The first of these suggested that 
KSR represented a new MAPKKK, possibly leading to the discovery of a novel corresponding 
MAPKK and MAPK.  In this model, KSR would be directly activated by Ras, and function in 
parallel to Raf.  The second model suggested that KSR was a co-activator of Raf.  Upon 
activation of a receptor tyrosine kinase, a pathway would be activated in parallel to Ras, leading 
ultimately to the activation of KSR, and consequent amplification of Raf activation.  Finally, it 
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 was postulated that KSR was an activator of Raf-1, serving as an intermediate step between Ras 
and Raf-1 activation [43].  These models have since been abandoned in the literature in favor of 
the role of KSR as a scaffolding molecule, as discussed in Section 1.5.4.3 – Scaffold. 
1.5.4.2. Kinase 
The most significant feature of the kinase domain of KSR is located in subdomain II.  
Mammalian kinases contain an invariant lysine residue in this region which is essential for the 
binding of ATP [52].  Mammalian KSR-1 isoforms have an arginine in place of this lysine, as 
does C. elegans KSR-2 [43, 47].  Although this may seem to be a conservative mutation, 
previous work with other kinases has demonstrated that mutation of this conserved lysine residue 
to any other amino acid, even arginine, can abolish activity [53].  The majority of known kinases 
contain a consensus sequence in subdomain VIb HRDL(K/R/A)XXN, where D and N are 
invariant residues [52].  KSR, however, has a lysine substitution in place of the arginine in VIb, 
distinguishing it from the majority of other kinases.  Further, subdomain VIII has been 
implicated in substrate recognition specificity [52].  Although this region is highly conserved 
between KSR’s of different species, it differs from Raf-1 significantly enough to suggest that, if 
KSR was a kinase, its spectrum of substrates would be quite different from that of Raf [43]. 
In an effort to determine if KSR kinase activity is essential for function, complementation studies 
were performed using two kinase dead mutants of C. elegans.  Neither mutation of the 
magnesium-ATP binding motif (ceKSR K503M), nor the catalytic nucleophilic aspartate 
(ceKSR D618A) affected complementation [54], suggesting that the kinase function of the 
protein is immaterial to its role in signaling.  Although the catalytic function of this region is 
questionable, expression of the isolated kinase domain of KSR dominantly inhibits Ras signal 
transduction [55-57].  The mechanism of this inhibition has not yet been determined. 
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 Work by Kolesnick and colleagues has suggested that KSR is a ceramide-activated protein 
(CAP) kinase [58].  Additionally, using a special in vitro assay, they report that KSR 
phosphorylates Raf-1 at position 269, thus contributing to its activation by EGF [59].  Attempts 
have been made by other labs to corroborate these results, but with no success [60]. 
1.5.4.3. Scaffold 
KSR was originally suspected of having scaffolding functions when it was discovered to bind to 
a number of signaling proteins.  Demonstrable binding partners of KSR include Raf-1, MEK1/2, 
ERK1/2, G protein βγ, 14-3-3, Hsp70 and 90, cdc37, PP2A, and C-Tak1 [54, 57, 61-65].   
As KSR has been put forth as an ERK scaffold, a great deal of effort in the literature has been 
dedicated to characterizing its interaction with pathway components.  MEK is constitutively 
bound to KSR through the CA5 kinase domain, while association with ERK is Ras-dependent 
[66, 67].  The ERK1/2 binding site within KSR is an FxFP motif located in the serine/threonine-
rich CA4 region of the protein [68].  It is binding to MEK which appears to be essential for KSR 
function.  Mutations in mKSR-1 corresponding to loss-of-function alleles identified in C. elegans 
ksr-1 [44, 45] prevent MEK association.  Additionally, expression of exogenous of KSR shifts 
the apparent molecular weight of MEK from 44 to more than 700 kDa in cells, moving it into a 
complex which also contains ERK1/2 [54].   
The interaction of KSR with Raf-1, however, is not quite so straightforward, and appears to be 
species specific.  This complex is most easily detected in Drosophila S2 cells, where Raf and 
KSR appear to be constitutively associated [50].  One of the loss-of-function mutations of KSR 
previously isolated in Drosophila (KSRL50S-R51G) corresponds to a mutation in the CA1 region of 
the protein [63].  Further examination of this mutant reveals that it has a decreased ability to bind 
Raf, indicating that KSR/Raf binding is mediated by the CA1 domain of DmKSR [50], and that 
18 
 this constitutive binding is essential for function.  In contrast, the detection of mKSR and Raf 
complexes is only possible in the membrane fraction of stimulated cells [64].  This agonist and 
membrane dependence of murine Raf/KSR interaction is consistent with the data reporting that 
KSR translocates from the cytosol in response to cell stimulation [62, 64, 65, 69, 70].  
Furthermore, Raf activation requires its relocation to the plasma membrane as well, a necessary 
event for its interaction with Ras.  Ergo, only when KSR and Raf are both localized to the plasma 
membrane can Raf be activated, subsequently phosphorylate KSR-bound MEK, and successfully 
propagate the signal. 
The most compelling evidence for KSR’s role as a scaffolding molecule came about through 
overexpression experiments.  Loss-of-function studies in invertebrates demonstrate the 
unequivocal necessity of KSR for Ras-mediated signaling.  Therefore, it was initially perplexing 
that, at high levels of KSR expression, Ras signaling was inhibited.  Further analysis of this 
phenomenon revealed that, at low levels, KSR did indeed enhance signaling.  Increasing KSR 
expression, however, inhibited ERK-dependent processes in a number of systems, such as R7 
photoreceptor development in Drosophila and germinal vesicle breakdown in Xenopus oocytes 
[56, 57, 61, 67].   
It is not surprising that KSR affects Ras pathway activation in a biphasic manner.  MAPK 
signaling components exist in limited quantities in cells, which would suggest a corresponding 
optimum concentration of scaffold to facilitate signaling.  Exceeding this optimum scaffold to 
signal protein ratio would therefore be predicted to segregate signal components from one 
another instead of enabling their activation [71].  In other words, excessive levels of KSR would 
increase the incidence of non-functional signal complexes, namely those lacking a complete 
repertoire of proteins required for signal coupling.  Accordingly, increased expression of Raf and 
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 MEK has been demonstrated to overcome this inhibition, and restore pathway activation in 
Drosophila [50], ostensibly by increasing the probability of a complete scaffold signal complex.  
Thus, based on the protein interactions of KSR and the overexpression data, this protein has been 
firmly established as an ERK scaffold. 
While endogenous levels of KSR-1 have, to date, been shown to augment ERK phosphorylation, 
hKSR-2 is purportedly a signaling inhibitor.  Recent studies with hKSR-2 have demonstrated 
that it is a negative regulator of Cot, a MAP3K family member involved in regulation of 
inflammatory and oncogenic signaling.  Cot controls interleukin-8 production, which is thought 
to be mediated by ERK and NF-κB signaling.  Overexpression of hKSR-2 selectively inhibits 
Cot-mediated ERK activation, while Ras-induced ERK signaling is unaffected.  This is 
intriguing, as hKSR-2 also interacts with Raf, MEK, and ERK, but appears to selectively inhibit 
the Cot pathway [48].  The most recent work with this isoform suggests that hKSR-2 also blocks 
MEKK3 activation, an additional MAP3K implicated in the inflammation response.  Activation 
of MEKK3 leads to ERK and JNK phosphorylation, as well as activation of the NF-κB pathway.  
hKSR-2-mediated inhibition of this signaling results in an inhibition of interleukin-8 production.  
Of interest, however, is the selectivity of this negative regulation: no effects were seen on other 
MAP3K’s, such as MEKK4, TAK1, or Raf [72].  Consequently, hKSR-1 represents not only an 
additional scaffold for MAPK signaling, but a potential mediator of pathway selectivity as well. 
1.5.5. KSR and the plasma membrane 
A number of studies have demonstrated that KSR shuttles between the cytosol and the plasma 
membrane.  In quiescent cells, its localization is mainly cytosolic.  Upon addition of various 
agonists, including serum, EGF, and PDGF, there is a rapid translocation of KSR to the 
membrane compartment [62, 64, 65, 69, 70].  Membrane association of KSR is essential but not 
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 sufficient for its function; artificial targeting by myristoylation does not activate the protein [60].  
Although this traffic has been reported in a number of cell types in response to various agonists, 
the actual mechanism by which KSR is recruited to the membrane has not yet been elucidated. 
1.5.5.1. The C1 domain 
One of the initial studies characterizing KSR showed its murine isoform to cooperate with 
oncogenic Ras and enhance Xenopus oocyte meiotic maturation.  This augmentation occurred at 
the level of MEK1 and MAPK, in that mKSR enhanced the kinetics of their activation [63].  
Further studies demonstrated the cysteine-rich C1 domain was necessary and sufficient for this 
signal augmentation.  In order to examine the role of this region, cysteines 359 and 362 in the 
CRD were mutated to serines (KSR CRM mutant).  Whereas wild type mKSR accelerated 
Xenopus oocyte maturation induced by activated Ras, the CRM mutant had no such effect.  
Furthermore, expression of the CRD of KSR alone enhanced maturation, while the same 
construct containing the CRM mutation did not.  Interestingly, the researchers report (in data not 
shown) that the rate of maturation is equivalent in oocytes injected with RasV12 alone and those 
with both RasV12 and KSR CRM, prompting them to conclude that mutation of the CRD does not 
generate a dominant negative KSR [60]. 
The mechanism by which the CRD mediates the cooperation between KSR and oncogenic Ras is 
still unclear.  Additional studies have suggested that this region is required for KSR membrane 
localization.  In 293 cells, the distribution of ectopically expressed mKSR1 was exclusively 
cytosolic.  Co-transfection of KSR and RasV12 caused a pool of wild type KSR to redistribute to 
the membrane compartment, while CRM KSR remained in the cytosol.  Work by another group 
has shown the CRD to be essential for the interaction of KSR with G-protein βγ subunits [69], 
although the significance of this interaction has not been extensively studied. 
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 Despite the similarity between the CRD of KSR and Raf-1, these sequences are not 
interchangeable [70].  The C1 domains in these two proteins have the most homology with those 
classed as atypical, such as PKCγ.  Unlike typical C1 domains, the atypical class do not interact 
with diacylglycerol (DAG) or phorbol esters [73].  Swapping the CRD of Raf-1 with either the 
CA3 region of KSR or the C1b domain of PKCγ abrogates its ability to activate MEK.  Further, 
substitution of the Raf-1 CRD into KSR renders it unable to enhance oocyte maturation [70].  
Further studies by this group demonstrated that membrane association of KSR is necessary but 
not sufficient for its functional contribution to Ras signaling.  Artificial targeting of KSR to the 
membrane by myristoylation did not affect its ability to cooperate with oncogenic Ras, but was 
also not sufficient to promote oocyte germinal vesicle breakdown [60].   
Taken together, the data pertaining to the KSR C1 domain indicate that this region of the protein 
is required for folding or function, but it not yet understood how this is accomplished.  
Moreover, although it has been reported that the CRD is essential for membrane recruitment, the 
mechanism by which this region may be involved in KSR traffic has not yet been determined. 
1.5.5.2. Phosphorylation-regulated trafficking 
The first studies to explore the role of phosphorylation in KSR function revealed there to be a 
number of target sites in the N-terminal non-catalytic region.  Phosphorylation of T260, T274, 
and S443 is induced by activated Ras, while S297 and S392 are phosphorylated in quiescent cells 
[67].  Phospho-serines at position 297 and 392 form consensus sites for 14-3-3 protein binding 
[62, 67].  These sites are essential for this interaction; alanine substitution at either S297 or S392 
reduces the amount of 14-3-3 bound to KSR, while mutation of both residues eliminates it 
completely [67].  S392 is dephosphorylated in response to growth factor treatment, while there is 
no detectable change in phosphorylation at position 297 in response to EGF or PDGF.  
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 Fractionation and immunostaining has also shown KSR S392A is constitutively associated with 
the membrane [62, 65], which results in enhanced ERK phosphorylation [62].  Together, these 
data suggest a model in which KSR is sequestered in the cytoplasm in quiescent cells by 14-3-3 
proteins binding to phosphorylated S392. 
Since neither kinase domain deletion nor kinase-dead mutants of KSR demonstrate decreased 
phosphorylation, these sites are not the result of autophosphorylation [74].  As mentioned above, 
KSR resides in cells as part of a large multi-protein complex, which has been shown to include 
Cdc25-associated kinase (C-TAK1).  C-TAK1 phosphorylates KSR in vitro, and mutations  
which eliminate this interaction inhibit phosphorylation of KSR in vivo [62].  Hence C-TAK1 
functions to retain KSR in the cytoplasm by phosphorylation of the 14-3-3 interaction site.  
Furthermore, since membrane association is required for KSR function, C-TAK1 constitutive 
association with KSR also represents a mechanism by which signaling could be terminated very 
quickly by redistribution of the scaffold back into the cytosol. 
Recent studies have identified protein phosphatase 2A (PP2A) as the phosphatase required for 
KSR membrane translocation.  PP2A structural and catalytic subunits (A and C, respectively) are 
constitutively bound to KSR within the N-terminal region, while association of the regulatory B 
subunit is agonist-dependent.  Specific inhibition of PP2A with okadaic acid results in a dramatic 
increase in phosphorylation at position 392, and sequesters KSR in the cytoplasm.  It also 
appears that bound 14-3-3 obscures the ERK binding site on KSR, as treatment with okadaic acid 
also reduces scaffolded ERK [65].  Interestingly, it has been shown previously that PP2A-
mediated dephosphorylation of S259 and subsequent dissociation of 14-3-3 of Raf-1 is a critical 
step in its activation [75].  Thus, for both KSR and Raf-1, membrane association and therefore 
activation is gated by PP2A.   
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Figure 4 – KSR trafficking between the cytosol and the plasma membrane 
 
A) S392 is located very close to the CRD in KSR.  Additionally, the PABR of KSR is depicted 
aligned with that of Raf-1. Color coding of domains is as in Figure 3, see legend. Identical 
residues are shown in red, and the PBM is underlined.  B) See text for additional details.  Briefly, 
KSR traffic has been reported to be dependent on the phosphorylation state of S392.  When S392 
is phosphorylated, 14-3-3 proteins associate with KSR and sequester it in the cytosol.  
Dephosphorylation of this residue leads to the release of 14-3-3, and allows KSR to move to the 
plasma membrane. 
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 1.5.5.3. A theoretical model for KSR traffic 
A potential model to combine all KSR trafficking data is as follows (Figure 4).  Upon growth 
factor stimulation of cells, KSR S392 is rapidly dephosphorylated by associated PP2A, allowing 
for dissociation of 14-3-3 proteins.  The proximity of the CRD to the S392 site where 14-3-3 
binds suggests that association of 14-3-3 may mask this region.  Dissociation of 14-3-3 would 
expose the C1 domain, thereby allowing it to facilitate KSR membrane recruitment.  
Furthermore, although MEK binding is unchanged, S392A KSR shows increased levels of ERK 
association, indicating the ERK binding site on KSR may be obscured by 14-3-3 binding [62].  
Thus, dephosphorylation of KSR also allows for access of ERK to the scaffold.  Once Raf-1, 
KSR, MEK and ERK are all colocalized in the membrane compartment, signaling can take place.  
Upon termination of the stimulus, bound C-TAK1 phosphorylates KSR on S392, prompting the 
reassociation of 14-3-3 proteins, movement of the scaffold into the cytosol, and prevention of 
any additional ERK binding. 
It is important to note that, although this model and all data reported address the importance of 
KSR membrane recruitment, how this event occurs has not been determined.  The CA3 CRD has 
been reported to be critical for KSR traffic, but neither a protein nor a lipid target for this region 
has been identified.  Thus, while membrane association of KSR appears to be essential for its 
function, the mechanism underlying this membrane recruitment is unknown. 
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1.6. Statement of the problem 
The purpose of this thesis work was to investigate the role of lipid-binding in the scaffolding 
function of KSR.  Membrane recruitment is essential for the ability of KSR to augment ERK 
activation; however, the mechanism of this translocation remains elusive.  Previous work in the 
laboratory with Raf-1 has demonstrated that its membrane recruitment is mediated by direct 
interaction with PA in the membrane.  Furthermore, mutation of the PBM renders Raf-1 
incapable of membrane association.  As KSR possesses an almost identical PABR, the following 
hypotheses were proposed: 
 1.  The PABR of KSR interacts with PA, and this interaction can be affected by 
neutralization of the PBM. 
 2.  Mutation of the KSR PABR will be detrimental to its ability to bind membranes and 
facilitate ERK activation. 
The testing of these two hypotheses are described below in Chapters 2 and 3, respectively.  
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 2. Lipid binding analysis of the KSR PABR 
2.1. Introduction 
Lipid second messengers are emerging as essential regulators of many signaling systems.  One of 
these, phosphatidic acid (PA), has been implicated in multiple cellular processes including 
endocytosis [76-78], activation of PI4P 5-kinase [79], apoptosis [80], and activation of the 
MAP3K Raf-1 [7, 10].  PA synthesis in cells can occur by several different processes: 1) 
diacylglycerol (DAG) phosphorylation by DAG kinase, 2) lyso-PA acylation by acyl 
transferases, and 3) phospholipase D (PLD) mediated hydrolysis of phosphatidylcholine [9].  PA 
also serves as a substrate for lipid modifying enzymes.  PA phosphohydrolases (PAP’s) convert 
PA into diacylglycerol, while phospholipase A2 removes an acyl chain to generate lyso-PA [80].  
A number of PA-binding proteins have been described (Table 1).  Phospholipase Cγ is activated 
by PA [81], while Ras-GAP is inhibited [82].  The function of mammalian Target of Rapamycin 
(mTOR) is also regulated by PA, the production of which recent studies have attributed to DAG 
kinase ζ [83].  Additional targets of PA include the protein tyrosine phosphatase SHP-1 [84], and 
phosphodiesterase-4 [85]. 
Of particular interest, work with Raf-1 has established PA association as a critical step in its 
membrane recruitment and therefore activation.  Mutations that disable PA-binding prevent Raf-
1 membrane association and generate a dominant negative for ERK phosphorylation [7, 10].  The 
Raf-1 PABR is characterized by hydrophobic residues flanking a poly-basic motif (PBM) 
comprised of two arginine residues [4].  Alanine substitution within the PBM eliminates PA 
binding [6, 7].  Increasing concentrations of salt do not disrupt the protein lipid interaction, 
however; thus, binding is not exclusively mediated by electrostatic interactions.  Furthermore, 
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 lipid binding of the Raf-1 PABR is specific for PA and highly cooperative, while binding to 
other basic lipids and phosphatidyl alcohols was negligible [4].   
The Kinase Suppressor of Ras (KSR) is a scaffolding protein for the ERK pathway originally 
identified in genetic screens for modifiers of an activated Ras phenotype [43-45].  Membrane 
recruitment of KSR has been reported in response to various agonists, and has been determined 
to be essential for its function in ERK cascade coupling [62, 64, 65, 69, 70].  Although it has 
been reported that the N-terminal cysteine rich domain is essential for KSR membrane 
association [60, 70], the mechanism underlying this recruitment has not been determined.   
KSR shares a great deal of sequence similarity with Raf-1, especially within its putative C-
terminal kinase domain.  This region contains an almost identical PABR, a sequence which is 
conserved in all identified KSR isoforms.  Using tryptophan-containing peptides corresponding 
to the PABR of KSR, the work in this chapter explores the lipid binding properties of this region.  
PA induces a blue-shift in the emission spectra of the WT peptide.  This fluorescence change is 
specific for PA; no change is observed in the presence of phosphoinositides, 
phosphatidylcholine, or phosphatidylserine.  This change in maxima is specifically induced by 
long chain PA’s, and maximum fluorescence changes vary with the saturation of the 
hydrophobic chain.  Furthermore, circular dichroism analysis of the PABR peptides reveals there 
to be a significant spectral change of the WT in the presence of lipid.  This change is not 
observed with a PBM mutant peptide (R612A, R615A).  Taken together, these data suggest a 
direct KSR-lipid interaction. 
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 Table 1 – PABR sequence alignment of Raf-1 and KSR  
 
The PABR is highly conserved among Raf and KSR isoforms.  The basic structural features of 
this domain in Raf and KSR include the poly-basic domain (underlined) and hydrophobic 
sequences on either side.  Color coding of amino acids is as follows: green=non-polar, 
red=positively charged, purple=negatively charged, black=uncharged, polar. 
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 2.2.  Methods 
2.2.1. Materials 
DOPA, POPA, DPPA, C6-PA, Egg PC, and DOPS were obtained from Avanti Polar Lipids 
(Alabaster, AL).  PI, PI3P, PI3,4P, PI3,5P, PI4,5P, and PI3,4,5P were purchased from Echelon 
Biosciences (Salt Lake City, UT).  Peptides were synthesized and biotin-conjugated by the 
Molecular Medicine Institute Peptide Synthesis Facility (Pittsburgh, PA).  Peptides were purified 
and determined by HPLC to be greater than 95% pure.   
2.2.2. Peptides 
Tryptophan-containing peptides corresponding to the PABR of WT KSR (FKKEVMN 
YRQTRHENVVLWMGACMNPPHLA) and MT KSR (FKKEVMNYAQTAHENVVLWMGA 
CMNPPHLA) were resuspended in 50mM Tris HCl, 100mM NaCL, and 100nM EGTA.  Lipids 
were prepared initially as micelles in the same buffer (pH 7.4) + 1% CHAPS.  Vesicles were 
prepared by dilution of detergent lipid solutions to well below the critical micelle concentration 
(CMC).  The CMC for CHAPS is 6-10mM, and the concentration of CHAPS in the samples was 
at most 300µM.  The pH of the experimental samples was maintained throughout at 7.4. 
2.2.3. Fluorescence measurements 
Tryptophan fluorescence values were acquired using a FluoroMax-3 spectrofluorometer 
equipped with single-grating excitation and emission monochrometers.  Excitation and emission 
slits were maintained at 5 nm, and measurements were made using a 1 x 1 cm quartz cuvette.  
Samples were excited at 280 nm, and emission was measured from 300-400 nm for full spectra, 
or at a constant 325 nm for titration experiments.  Each measurement reflects the average 
fluorescence over five seconds of acquisition.  Changes in fluorescence at 325 nm were plotted 
against log lipid concentration, and analyzed by curve fitting with GraphPad Prism software. 
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 2.2.4. Circular dichroism measurements 
CD measurements were taken of peptides ranging in concentration from 0.2-0.5mg/mL, in 
50mM Tris, pH 7.4 at 25°C, in the presence or absence of 50uM lipid and 18mM CHAPS.  All 
samples were horn-sonicated for 5 minutes just prior to analysis.  Measurements were taken 
using an AVIV instrument built on a Varian Cary 60 platform using AVIV data acquisition and 
data processing software.  Data reported reflects an average of ten spectra per sample.  CD data 
was analyzed using CDSSTR, from DICHROWEB (www.cryst.bbk.ac.uk/cdweb) using the built 
in databases available on the server (reference set 4 for the range 190-240 nm; data truncated at 
240 nm).  Analysis was confirmed using CDFIT (www.structure.llnl.gov/cd). 
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 2.3. Results and Discussion 
2.3.1. KSR PABR peptides interact with PA in vitro 
The fluorescence of tryptophan is determined by its environment.  Interactions between this 
amino acid and a hydrophobic milieu stabilize the dipole formed upon excitation, thus increasing 
the quantum yield and therefore fluorescence.  This makes tryptophan fluorescence a powerful 
tool for determining protein structure as well exploring protein-lipid interactions [86].  
Tryptophan spectroscopy and fluorescence quenchers have been used extensively to determine 
the kinetics of protein-protein and protein-lipid interactions [87] and insertion depth of 
membrane proteins [88, 89], as well as peptide-membrane topology [90]. 
Accordingly, peptides corresponding to the KSR PABR (amino acids 603-633) were synthesized 
containing a tryptophan substitution at the position analogous to F622.  These peptides are 
depicted in Figure 4.  Wild type KSR PABR (WT KSR) possessed an intact PBM, while the two 
arginine residues in the MT KSR peptide PBM (R612/615) were mutated to alanines.  Previous 
studies have shown that mutation of one or both of these arginine residues in the Raf-1 PABR 
results in an ablation of PA-binding [6, 7]. 
Sample emission traces of the two peptides are shown in Figure 5.  Emission scans were made of 
the peptides between 310 and 400 nm at a constant excitation wavelength of 280 nm.  In the 
absence of lipid, the emission maximum was 350 nm.  Addition of PA to the WT PABR 
produced an increase in fluorescence as well as a more than 10nm blue-shifting of the curve.  
The amplitude of tryptophan fluorescence blue shift has been correlated with depth of membrane 
insertion.  Emission maxima can shift from 337 nm for a tryptophan located near the membrane 
surface to 318 nm upon full insertion [88].  Structure of the PABR peptide supports this  
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Figure 5 – KSR PABR peptide design 
 
(A) Domain structure of mKSR-1, depicting the location of the putative PABR.  (B) PABR 
peptide sequences correspond to amino acids 607-636 of mKSR-1.  Tryptophan was substituted 
for the phenylalanine at position 622.  The underlined portion represents the PBM.  Arginines 
612 and 615 were mutated to alanines to produce the MT KSR peptide. 
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 possibility, in that the PBM is surrounded by hydrophobic sequences ideal for membrane 
intercalation.  Changes in fluorescence for the WT KSR peptide were detectable at nanomolar 
concentrations of lipid, while no change was observed in the MT KSR spectrum, even at lipid 
concentrations up to 10uM PA.   
Closer examination of the MT KSR PABR curve reveals the tryptophan emission maxima to be 
notably blue-shifted relative to the WT peptide in the absence of lipid.  This blue-shift indicates 
that in the case of the MT peptide, the milieu of the tryptophan residue is more hydrophobic than 
in the WT PABR.  This could either indicate a structural change in the MT peptide, or the MT 
PABR may be aggregating.  There is also no change in the emission peak of the MT peptide in 
the presence of lipid.  There are two possible explanations for this.  It is conceivable that the 
environment surrounding the tryptophan residue is so hydrophobic, binding of lipid does not 
change its fluorescent properties.  Alternatively, there may be no peptide-lipid interaction with 
the MT KSR PABR. 
In order to further explore the effects of lipids on the peptides, we conducted preliminary CD 
measurements to examine structural features of the PABR in the presence and absence of lipids 
in the WT and mutant peptides.  The CD spectra of the WT KSR are shown in Figure 7A. The 
spectrum appeared largely devoid of defined secondary structure.  Spectral deconvolution 
estimated WT KSR PABR to be composed of 70% random coil, with a very small beta-sheet and 
negligible alpha-helical component.  Upon addition of detergent micelles containing PA, there 
were significant changes in the spectrum that may be consistent with a large proportion of beta-
sheet content. Control experiments with detergent alone, or PC, which do not cause changes in 
fluorescence, did not cause these effects (data not shown).   
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 The CD spectra of  MT PABR are shown in Figure 7B. Overall, the spectra are qualitatively 
different from those observed for the WT, and deconvolution of the spectrum in the absence of 
lipid suggested an increase in random coil contribution to 90% as compared to the WT spectrum. 
Furthermore, we could not detect similarly drastic changes in the spectrum in response to lipid 
addition. It appears that there may be a small increase in helix content. - While these experiments 
need to be considered preliminary, they suggest that WT KSR PABR may undergo 
conformational changes upon the addition of PA, while the mutation of the PBM may cause a 
change in peptide structure as compared to the WT that directly or indirectly could be the cause 
for preventing lipid-induced conformational changes in the mutant.   
2.3.2. Changes in PABR fluorescence are specific for PA 
PA blue shifts the emission peak of the PABR tryptophan; thus, maximum fluorescence changes 
were easily detectable at a fixed emission wavelength of 325nm.  Table 2 summarizes data for 
lipids tested.  The shifting of the emission peak of KSR WT PABR was specific for phosphatidic 
acid; no change was detectable with phosphatidylserine, phosphatidylcholine or any of the 
phosphoinositides.  Four different PA’s were tested, dioleoyl PA (DOPA, C18:1), dipalmitoyl 
PA (DPPA, C16:0), palmitoyl oleoyl PA (POPA, C16:0-18:1), and dicaproyl PA (C-6 PA, C6:0).  
The PA’s with longer acyl chains, DOPA, DPPA, and POPA, affected the emission peak of WT 
KSR PABR with half-maximal values of 1266nM, 1242nM, and 841nM, respectively.  This 
effect was determined to be non-cooperative; Hill coefficients obtained through curve-fitting 
were approximately 1.  The short-chain C-6 PA, however, had no effect on the fluorescence of 
the peptide (Figure 8A). 
Additionally, acyl chain composition affects observed fluorescence values.  Although the 
calculated EC50 values for DOPA, DPPA, and POPA are not statistically distinct, addition of  
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Figure 6 – DOPA induces a blue-shift in the emission peak for WT KSR PABR but not MT KSR PABR 
 
Samples containing 200nM peptide were excited at 280nm, and emission scans were collected 
between 310nm and 400nm.  A blue-shift in WT KSR fluorescence is detectable at 
submicromolar concentrations of lipid, but no change is observed in the MT even at 
concentrations of 10µM.  The ideal control for this experiment would be to demonstrate binding 
of the Raf-1 PABR to PA as well.  Unfortunately, no fluorescence change was detectable in the 
Raf-1 peptide upon addition of lipid.  This may be due to a problem with the peptide, however, 
as synthesis of the Raf-1 PABR was reported to be problematic by the Peptide Facility.  They, 
and other synthesis facilities contacted, reported that synthesis of a Raf-1 MT PABR was 
virtually impossible, due to the extremely hydrophobic nature of the mutant peptide.  The 
substitution of negatively charged residues instead of alanine within the PBM may prove a 
means by which to avoid this problem.  Additional experiments will also be required to verify 
that the tryptophan residue does not affect function in the full-length protein. 
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Figure 7 – CD spectra of WT and MT KSR 
 
CD spectra for WT (A) and MT (B) KSR PABR peptides were analyzed using NCI’s CD-Fit 
software.  For analysis details, see Materials and Methods.  WT KSR contains 70% ± 15% 
random coil in the absence of lipid, and 70% ± 15% β-sheet in the presence of 100uM PA 
detergent micelles.  MT KSR contains 90% ± 15% random coil, and this composition does not 
significantly change upon addition of PA micelles.  Furthermore, no conformational change was 
observed with either peptide in the presence of detergent alone or PC micelles (data not shown).   
(Data contained in this figure and the corresponding methods were designed, generated, and 
presented as reported by G. Romero). 
37 
  
Table 2 – Calculated affinities of KSR PABR for lipids 
 
38 
 lipid caused significantly different changes in the fluorescence (Figure 8B).  From the sigmoidal 
curve fit, theoretical maximum values were calculated for each lipid.  The top of the DOPA 
curve (37122 ± 1594) was 2.9 times that of the POPA (12732 ± 2814), and 3.5 times the DPPA 
value (10527 ± 1957).  The structure of these three lipids is shown in Figure 9, and their 
transition temperatures, defined as the temperature at which a lipid will transition from a rigid 
gel phase into the more fluid liquid crystalline state, are as follows: DOPA -8°C, POPA 28°C, 
DPPA 67°C.  All binding experiments were performed at room temperature (22°C), meaning that 
only DOPA is in the liquid crystalline phase.   
Although more work is needed to establish a link between tryptophan levels in the KSR peptides 
and the fluidity of the lipid phase, it is interesting to speculate on the observed differences 
between DOPA and the other lipids with lower transition temperatures.  We propose that the 
maximum levels of tryptophan fluorescence change are observed when the PABR is in the 
presence of vesicles composed of more fluid membrane, increased membrane fluidity possibly 
facilitating peptide insertion.  Moreover, the apparent preference of the PABR for the less 
saturated lipids is supported by in vivo studies with PLD.  Work in the Romero lab has 
determined PLD2 as the source of the PA required for Raf-1 membrane requirement through the 
PABR [10].  The two most abundant PA species generated in stimulated cells by PLD2 are 
POPA and DOPA, representing 20.5% and 12.8% total PA, respectively [91]. 
It is also of interest that the peptide is selective for PA compared to the similarly negatively 
charged PS.  PA is not a particularly abundant membrane lipid.  In erythrocyte plasma 
membrane, for example, PA comprises less than 1.5% of the membrane, compared to the 8% 
determined to be PS1.  To date there have been no reports determining ratio of PA to PS 
specifically for the endosomal compartment, where the Ras/ERK  
                                                 
1 Sanderson JM. Org Biomol Chem. 2005. 3(2):201-12. 
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 signaling components assemble.  Previous work in our lab has shown that treatment of HIRcB 
cells with insulin results in a greater than five-fold increase in endosomal PA.  Assuming a 
constant level of PS between the plasma membrane and the endosome, stimulation with insulin 
results in a five-fold increase in the PA:PS ratio.  Moreover, concentration of PA into 
microdomains may result in local exclusion of other negatively charged phospholipids.  The 
observed selectivity of the PABR for PA may facilitate specific localization of Raf and KSR to 
lipid microenvironments, such as the PA-enriched endosome.  Moreover, the CD studies 
discussed above did not include exploration of the effects of PS on PABR structure.  It is 
possible that the energy of interaction associated with any peptide:PS interaction is insufficient 
to induce required specific conformational changes.  Thus, although an association between the 
PABR and PS may be possible, it could be an ineffectual one.  Finally, it is important to note that 
the peptide studies presented are reductionist, and that binding of the whole protein to lipids may 
differ from the isolated PABR, a point which remains to be explored in future studies. 
Binding properties of the PABR remain largely uncharacterized.  Early work with Raf-1 reported 
that PABR-PA binding was highly cooperative, with Hill coefficients ranging from 3.3 to 6.2.  
The same study also reported the apparent affinity of the PABR for PA to be 4.9-7.8% mol% PA 
[4].  It is important to note, however, that these values were determined using a solid phase 
binding assay, and do not provide an accurate representation of binding affinity.  Furthermore, 
the use of immobilized lipid renders their values less physiologically relevant.  Additional 
studies by Rapp and colleagues used surface plasmon resonance (SPR) and recombinant full-
length Raf-1 to explore this lipid interaction.  Using mixed composition liposomes, consisting of 
PC, PE, and sphingomyelin, they calculate the affinity of Raf-1 for PA to be 0.5nM [8].  This 
value bears further scrutiny, however.  The highest affinity reported to date for a lipid binding 
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 region is the PX domain of p47phox for PI3P, that being 50-100nM [92].  Moreover, the affinity 
of Ras for Raf is only 150nM [93].  Taking into account the possibility that the affinity of the 
full-length protein for lipid may be greater than for the binding region alone, it is still difficult to 
accept that the two values would be quite so disparate.  Thus, further analysis of lipid-PABR 
interactions is warranted to definitively determine lipid-binding affinity of this domain, both as 
an isolated peptide and in the context of the full-length protein. 
The data presented here strongly suggest a direct KSR lipid interaction.  Furthermore, a KSR 
mutation that changes the structure of the PABR and may eliminate lipid binding has been 
defined.  The cellular consequences of this mutation will be explored in the subsequent chapter. 
 
41 
  
 
Figure 8 – Maximal fluorescence changes are correlated with long-chain mono- or di-unsaturated PA’s   
 
(A) WT KSR peptides do not interact with short chain PA’s.  (B) Maximal fluorescence change 
is observed in the presence of DOPA (18:1), followed by POPA (16:0, 18:1) and DPPA (16:0).  
Theoretical tops of the curves (see text for details) were calculated with GraphPad Prism.  
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Figure 9 – Structures of various PA’s 
 
The defining characteristics of a PA molecule are the negatively charged headgroup, and the 
degree of saturation and length of the fatty acid chains.  Simple depictions of lipid structures are 
shown at right.  Membranes composed exclusively of DOPA, having two unsaturated acyl 
groups, are going to be more fluid than those made up of DPPA.  Transition temperatures of 
DOPA are much lower than the other lipids tested (<0°C), thus making it the only lipid in the 
liquid crystalline phase at room temperature. 
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 3.  Binding of phosphatidic acid is essential for KSR function as a facilitator of 
mitogen-activated protein kinase activation, but not its membrane association 
3.1. Introduction 
Recent work in the signaling field has shown that targeted membrane association of the 
components of the Ras/Raf/MEK/ERK signaling pathway is essential for their activation.  Ras is 
targeted to cholesterol rich microdomains in the plasma membrane [11], while Raf-1 has been 
shown to interact directly with membrane lipids, namely phosphatidic acid (PA) [4, 10] and 
phosphatidyl serine [8].  Following cell stimulation, activated components of the ERK1/2 
signaling pathway are localized to the surface of intracellular vesicles identified to be early 
endosomes [10, 15].  Neither ERK nor MEK possess any identified lipid binding regions, which 
suggests the involvement of additional scaffolding proteins in their membrane recruitment. 
To date, several scaffolding proteins have been identified for the ERK1/2 pathway.  One of 
these, MEK1 partner (MP1), has been shown to specifically interact with and localize MEK1 and 
ERK1 to the surface of late endosomes and lysosomes.  This subcellular targeting is 
accomplished by the interaction of MP1 with p14, a small protein on the membrane surface.  
siRNA knockdown of MP1 results in cells defective in ERK signaling [34].  Furthermore, in the 
absence of p14, MP1 is unable to associate with lysosomes, and the efficiency of ERK signaling 
is compromised [34, 35]. 
A second scaffold which has proven much more enigmatic is the Kinase Suppressor of Ras 
(KSR).  KSR has been shown to interact with MEK1/2 [51, 54, 57, 61, 94], ERK1/2 [51, 57, 67], 
and Raf-1 [64] in vivo.  Furthermore, KSR shuttles between the cytoplasm and the plasma 
membrane in response to agonists.  In quiescent cells, its localization is mainly cytosolic; 
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 however, upon stimulation with agonist, there is a rapid translocation of KSR to the membrane 
compartment [62, 64, 65, 69, 70]. 
Sequence analysis of KSR reveals two well-defined lipid-binding motifs: an N-terminal C1 
domain and a C-terminal PA-binding region (PABR).  It has been suggested that the cysteine-
rich C1 domain (CRD) may be involved in membrane binding [60, 70].  The CRD is located 
within the CA3 region of KSR, and is homologous to the atypical C1 domain of Raf-1.  A bona 
fide lipid target for the CRD has not yet been found, although unpublished data by Morrison et al 
has ruled out ceramide and phorbol esters [70].  The PA-binding region (PABR) is located in the 
kinase domain of KSR.  Like that of Raf-1, the KSR PABR consists of a positively charged poly-
basic motif (PBM) flanked by hydrophobic segments.  Neutralization of the PBM has been 
shown to disable membrane binding in Raf-1 [7]. 
Data presented in this section demonstrate that mutation of the KSR PABR (MT KSR) generates 
a dominant negative for ERK phosphorylation.   Furthermore, MT KSR is an agonist specific 
dominant negative, in that it inhibits ERK phosphorylation in response to insulin, but not EGF.  
Surprisingly, the subcellular localization of KSR is not changed with the PABR mutation.  Both 
WT and MT KSR traffic constitutively between the cytoplasm and the membrane fraction 
independent of stimulation.  Finally, both WT and MT KSR are found in the endosomal 
compartment, independent of PA-binding.  Taken together, these data suggest that an intact 
PABR may not be necessary for recruitment of KSR to membranes, but it is essential for proper 
coupling of the signaling pathway. 
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 3.2. Methods 
3.2.1. Cell culture 
HIRcB cells, rat-1 fibroblasts overexpressing human insulin receptor, were cultured at 37°C and 
5% CO2 in DMEM-F12 media supplemented with 10% fetal bovine serum and 100nM 
methotrexate.  Cells destined for imaging experiments were transfected using Superfect 
(Qiagen), while Lipofectamine 2000 (Gibco) was used for biochemical samples, as per the 
manufacturers instructions.  NIH-3T3 cells were treated as above, but grown in DMEM + 10% 
fetal calf serum. 
3.2.2. Plamids 
Plasmids encoding mKSR-1 were kindly supplied by Dr. Richard Kolesnick and Dr. Kun-Liang 
Guan.  KSR was amplified by PCR and subcloned into eGFP C1 vector (Clontech) using the 
EcoRI and SalI restriction sites.  HA WT KSR was generated by PCR amplication and 
subsequent cloning into pCMV-HA (BD Biosciences) using the NotI and BglII sites.  
R612/615A KSR (MT KSR) was made by the four primer PCR method. 
3.2.3. Antibodies 
Primary antibodies used were as follows: mouse anti-EEA-1 (Transduction Laboratories); rabbit 
anti-MEK, rabbit anti-ERK1/2, rabbit anti phospho-MEK, mouse anti-phospho ERK1/2 E10 
clone (Cell Signaling Technology); mouse anti-HA ascites fluid (Covance).  All primary 
antibodies were used at a concentration of 1:1000.  Horseradish peroxidase conjugated secondary 
antibodies (Pierce) were used at 1:5000. 
3.2.4. Cell fractionation 
HIRcB cells were transfected with pCMV HA-KSR WT or MT, and serum starved overnight.  
After stimulation with 200nM insulin, cells were washed with PBS on ice, and scraped in cell 
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 cracking buffer (10mM HEPES pH 7.4, 2mM EDTA, 1mM Na3VO4, 50mM NaF, 1ug/mL 
leupeptin).  Cells were then broken by 20 passes through a 22.5 gauge needle, and spun at 3000 
RPM at 4°C for ten minutes to remove nuclei and unbroken cells.  Soluble and particulate 
fractions were separated by a 90 minute 100,000 x g spin at 4°C.  Pellets were resuspended in 
Laemmli buffer, and equal amounts of cytosol and membrane fractions were loaded on 10% 
acrylamide gels for Western blotting.  Resultant blots were probed with anti-HA antibody.   
3.2.5. Endosome isolation 
Endosomes were isolated as previously described [15].  Briefly, HIRcB cells were transfected 
with WT or MT KSR, and serum starved overnight.  Cells were incubated with ferro-insulin 
conjugates for 20 minutes at 37°C, and scraped in homogenization buffer (1 mM Hepes, pH 7.2, 
1 mM EDTA, 25 mM sucrose, 1mM NaVO4, 50mM NaF), broken by 20 passes through a 22.5 
gauge needle, and loaded onto columns in a magnetic field.  Endosomes were eluted from the 
columns using homogenization buffer + 0.5% TX-100.  Samples were boiled in Laemmli buffer, 
run on 10% acrylamide gels, and Western blotted with anti-HA antibodies. 
3.2.6. Live cell imaging 
Cells were plated on 35mm poly-L-lysine coated coverslip dishes (MatTek), and transfected with 
eGFP-KSR WT or KSR MT constructs using Superfect Transfection Reagent (Qiagen).  Cells 
were imaged at 37°C by placing the coverslip dish in a microperfusion incubator (Medical 
Systems Corp.).  Images were acquired using a Zeiss Pascal confocal microscope, equipped with 
a 63x oil immersion objective.  Samples were excited at 488nm, and emitted light was filtered 
through a 545nm long pass filter before photomultiplier detection. 
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 3.3. Results and Discussion 
3.3.1. MT KSR inhibits ERK and MEK phosphorylation in response to insulin 
Neutralization of the PBM of Raf-1 has been demonstrated to eliminate PA binding, and thus 
membrane interaction and activation [6, 7].  Data presented in Chapter 2 of this thesis likewise 
demonstrate the same mutation in the KSR PABR eliminates any detectable PA-induced changes 
in vitro.  In order to explore the cellular consequences of a KSR PABR mutant (MT KSR), the 
PBM arginine residues (R612/615) were mutated to alanines in the full-length protein.  These 
constructs were then expressed in rat-1 fibroblasts overexpressing the human insulin receptor 
(HIRcB cells).  Insulin-induced Ras/ERK signaling and the PA-dependent traffic of Raf-1 have 
been extensively characterized in this system [7, 10, 11, 15]. 
Mutation of the Raf-1 PBM generates a mutant which dominantly inhibits ERK phosphorylation 
in response to insulin, ostensibly by its inability to associate with the membrane compartment 
[7].  We therefore initially sought to determine if an intact KSR PABR is required for ERK 
activation.  HIRcB cells were transfected with either empty pCMV-HA vector, HA-WT KSR, or 
HA-MT KSR, and serum starved overnight.  Cell lysates were analyzed by SDS-PAGE, and 
Western blotted with antibodies specific for phosphorylated ERK.  As shown in Figure 9A, MT 
KSR is a potent dominant negative for ERK phosphorylation, while WT KSR had no effect.  A 
similar inhibition is seen for the ERK kinase, MEK (Figure 11A).  Furthermore, this inhibition is 
dose dependent.  Low levels of MT KSR expression have no effect; however, inhibition at higher 
doses is profound.  These data demonstrate that an intact KSR PABR is required for ERK 
activation, and mutation of this domain generates a dominant negative for the pathway.   
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Figure 10 – MT KSR inhibits ERK phosphorylation in response to insulin, but not EGF 
 
HIRcB cells were transfected with empty pCMV-HA vector, HA-WT KSR, or HA-MT KSR 
using Lipofectamine 2000 in the absence of serum.  On the day following transfection, cells were 
stimulated with 200nM insulin (A) or 100ng/mL EGF (B) for 10 minutes at 37°C, washed with 
PBS, scraped and lysed in hot Laemmli buffer.  Samples were sonicated and boiled prior to 
separation on a 10% acrylamide gel.  Western blots were probed with antibodies specific for 
phospho-ERK.  Samples represent equal numbers of cells plated the day prior to transfection, 
and no significant cell loss was observed following transfection with any construct used.  
Transfection efficiency was greater than 75%, as determined by a visual assay using GFP-labeled 
KSR (data not shown).  One-way ANOVA and Dunnet’s post test were used to determine that 
MT KSR (**) is significantly different from WT KSR (*) in the insulin treatment, but not the 
EGF.  (n=3)  Preliminary experiments conducted expressing comparable levels of KSR in these 
cells showed no significant change in total ERK expression upon transfection with the MT, but 
further studies will be required to confirm this result (data not shown). 
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Figure 11 – MT KSR inhibits MEK phosphorylation in response to insulin, but not EGF 
 
Samples were treated exactly as described in Figure 9 for ERK phosphorylation, except Western 
blots were probed with antibodies against phosphorylated MEK.  (n=3) 
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Figure 12 – MT KSR inhibition of ERK phosphorylation is dose-dependent 
 
HIRcB cells were handled as has already been described.  One-way ANOVA and Dunnet’s post-
test determined that the difference between the two doses of MT KSR are significant, while there 
is no significant change with higher doses of WT KSR. 
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 3.3.2. Dominant negative effects of MT KSR are specific for insulin signaling 
The Ras/ERK cascade is activated by a variety of agonists, and scaffolding proteins have been 
suggested as possible mediators of pathway specificity.  We therefore investigated the necessity 
of the PABR in epidermal growth factor (EGF)-mediated activation of ERK.  Intriguingly, MT 
KSR had no effect on the phosphorylation of MEK and ERK in response to EGF (Figure 10B, 
11B).  This data can be interpreted one of two ways: either KSR is not required for EGF 
signaling in HIRcB cells, or activation of ERK in this pathway does not require the KSR PABR. 
The idea of a scaffold having an agonist-specific function is not without precedent.  MEK-
partner 1, for example, has been reported to be essential for Pak-mediated activation of MEK in 
response to fibronectin.  siRNA knockdown of MP1 had no effect on MEK phosphorylation 
stimulated by PDGF [37].  Yeast scaffolds have also been implicated in specificity of pathway 
response.  The high osmolarity response and mating pathways share the same MAP3K, but differ 
in the ultimate MAPK activated.  Using different MAP3K-scaffold fusion, studies have shown 
that MAPK specificity is conferred by the scaffolding protein [25]. 
3.3.3. MT KSR interacts with membranes independently of agonist 
Raf-1 interaction with membranes absolutely requires an intact PABR.  Mutation of even one of 
the PBM arginines results in a mutant that acts as a dominant negative for insulin-induced ERK 
phosphorylation, correlating with its inability to bind membranes [7].  Data presented in Chapter 
2 of this thesis demonstrate that a similar mutation in the KSR PABR affects PA binding.  Thus, 
we sought to determine if the dominant negative effect of MT KSR was associated with a loss of 
membrane association.  HIR cells were transfected with either HA-WT KSR or HA-MT KSR, 
disrupted in detergent-free buffer, and separated by a 90 minute centrifugation at 100,000x g.  
The isolated soluble (S) and particulate (P) fractions were boiled in Laemmli buffer, and  
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 analyzed by SDS-PAGE.  Western blots were probed with an antibody recognizing the HA 
epitope tag, and results are shown in Figure 13A.  The amount of KSR in the S and P fractions 
was quantified by densitometry, and expressed as a fraction of the total amount of KSR detected.  
Surprisingly, there was no apparent difference in the membrane association of WT and MT KSR.  
Furthermore, there was also no change in KSR distribution in response to insulin.  One-way 
ANOVA confirms this observation; there is no significant difference between quiescent and 
stimulated cells, nor is there a difference between WT and MT KSR. 
These data are inconsistent with the reported model of KSR traffic in cells (for example, see 
[62]).  KSR is reported to be a cytosolic protein in quiescent cells, and only translocates to the 
membrane fraction in response to agonist.  Thus, it is conceivable that there may be a problem 
with our KSR constructs.  To rule out this possibility, HA-WT KSR was expressed in NIH-3T3 
cells, a cell type in which KSR traffic has been reported to be agonist dependent.  Studies using 
3T3 cells reported that approximately 25% of the total KSR associates with the membrane in 
quiescent cells, and increases to 70% in response to stimulation [64].  As shown in figure 13B, 
expression of our HA-WT KSR construct corroborates these results.  Thus, despite their 
homology, KSR and Raf-1 traffic is regulated by different mechanisms.  Furthermore, the equal 
distribution of KSR between the membrane and the cytosol appears to be unique to HIRcB cells. 
KSR membrane recruitment has been reported to hinge upon two factors.  The first of these is the 
N-terminal cysteine-rich domain (CRD).  Mutation of the cysteine residues in this region prevent 
association of the protein with the membrane [60, 70].  The CRD of KSR is similar to the 
atypical C1 domains of Raf-1 and PKC; however, the mechanism by which this region may  
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Figure 13 – WT and MT KSR associate with membrane independently of agonist 
 
(A) HIRcB cells were fractionated by centrifugation at 100,000g, as described in the text.  One-
way ANOVA detected no statistical difference between groups (n=3).  (B) Fractionation of NIH-
3T3 cells expressing HA-WT KSR.  Approximately 50% of KSR redistributes to the membrane 
in response to agonist in 3T3 cells. 
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 mediate membrane association is yet to be determined.  The second reported regulator of KSR 
traffic is 14-3-3 association, mediated by phosphorylation of serine 392.  Mutation of this residue 
to an alanine results in a KSR constitutively associated with the membrane [25].  These two 
models are not mutually exclusive, however.  Binding of 14-3-3 is very close to the CRD, 
implying that association to KSR may mask the CRD in quiescent cells.   
3.3.4. WT and MT KSR bind the surface of early endosomes 
Previous studies in the Romero lab have demonstrated that the components of the Ras/ERK 
signaling cascade assemble on the surface of early endosomes.  Endosomal localization of Ras, 
Raf-1, MEK, and ERK is agonist dependent, and blockade of endocytosis inhibits ERK 
phosphorylation [7, 15].  The localization of Ras and Raf to these “signaling endosomes” is not 
surprising, as both of these proteins are known to interact with membranes.  Neither MEK nor 
ERK possess any identified lipid binding domain, which suggests possible role for a scaffolding 
protein in their endosomal recruitment. 
We therefore next sought to determine if KSR could be found in the endosomal fraction of 
HIRcB cells.  Recent work in our lab has developed a novel method of isolating endosomes.  
Briefly, iron beads are conjugated to insulin, and internalized by the cells.  The cells are then 
mechanically disrupted by multiple passes through a small-gauge needle, and loaded onto 
columns in a magnetic field.  This technique allows for the specific isolation of endosomes 
containing activated insulin receptors [15].  Using this technique, we demonstrate that KSR 
associates with endosomes, and mutation of the PABR has no effect on this recruitment (Figure 
14B).   
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Figure 14 – KSR associates with the membrane and endosomal fractions independent of PA binding 
 
HIRcB cells were transfected with WT or MT KSR, as described previously.  Prior to 
stimulation with 200nM insulin, cells were incubated with 0.3% 1-butanol for 20 minutes at 
37%C.  For both the S100/P100 fractionation (A) and the magnetic endosome isolation (B), cells 
were collected and lysed after 20 minutes of agonist stimulation.  Western blots were probed 
with an antibody against the HA epitope tag. 
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 Localization of signaling molecules to specific subcellular localization is a common thread 
among scaffolding proteins.  The A-kinase anchoring proteins, for instance, target PKA to 
organelles in close proximity to its substrates [95].  An example of this is dual-specificity 
AKAP-1.  This scaffold tethers PKA to the surface of the mitochondria, where it phosphorylates 
and inactivates the pro-apoptotic BAD [96].  ERK scaffolds, too, have been reported to localize 
to specific subcellular locations.  MP1 has been reported to localize to the surface of late 
endosomes and lysosomes.  This lysosomal recruitment is mediated by MP1 interaction with p14 
[35].  A physiological role for MP1 targeting of MEK1 and ERK1 to the lysosomal surface has 
not been elucidated; however, mistargeting the complex to the plasma membrane inhibits ERK 
phosphorylation [34], indicating proper subcellular localization is essential for pathway coupling. 
3.3.5. WT and MT KSR traffic does not require PA or 3-phosphoinositides 
The data reported above seem to indicate that, although a functional KSR PABR is required for 
ERK phosphorylation, this domain is not implicated in membrane association.  In an effort to 
more fully explore the role of lipid binding in KSR traffic, we used inhibitors of PI3 kinase 
activity and PA-synthesis.  There are multiple pathways by which PA can be generated in cells; 
however, the activity of PLD2 has been determined to be essential for Raf-1 membrane 
translocation.  PA production by PLD-mediated hydrolysis of phosphatidylcholine can be 
inhibited by application of primary short-chain alcohols, which compete for water in the 
transphosphatidylation reaction.  This competition results in the synthesis of a 
phosphatidylalcohol instead of PA [97].  Since the PABR of Raf-1 does not bind 
phosphatidylalcohols [4], 1-butanol and 1-propanol treatments were ideal for PA synthesis 
inhibition in our model.  Only 0.25% of the total phosphoinositide in cells is phosphorylated at 
the 3 position [98], supporting the idea that these lipids serve a regulatory role in lieu of a  
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Figure 15 – KSR association with endosomes does not require binding of PA or a 3-phosphoinositide 
 
HIRcB cells were transfected with WT or MT KSR, stimulated with ferro-insulin complexes for 
20 minutes, and lysed.  Samples were analyzed by Western blotting against the HA epitope tag. 
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 structural one.  Of these 3-phosphoinositides, PI3P is enriched in the endosomal compartment, 
where it becomes the target of FYVE and PX domains [99].  PI3K inhibitors wortmannin and 
LY294002 were therefore used to rule out 3-PI contribution to KSR traffic. 
Cell fractionation studies depicted in Figure14A reveal that inhibition of PA production by 
butanol treatment does not affect KSR membrane association.  Likewise, KSR endosomal 
localization is unaffected by this treatment (Figure 14B).  It is not surprising that treatment with 
butanol reduces the amount of EEA-1 in the sample slightly, as PA has been implicated in 
endocytosis and membrane fission [78].  It is clear, however, that there is no significant decrease 
in the amount of KSR associated with the endosome fraction in the presence of a PA-synthesis 
inhibitor.  Additionally, neither wortmannin nor LY294002 treatment affected the presence of 
KSR in the endosome fraction (Figure 15.)  These data imply that KSR membrane association 
may be independent of lipid association, either with PA or 3-PI’s.  To strengthen this conclusion, 
a useful control would be to validate the lipid-altering drugs used in these studies.  For example, 
the efficacy of the LY294002 or wortmannin in inhibiting PI3K might be confirmed by 
incubation of cells with P32-orthophosphate, and measurement of PI levels relative to PI3P by 
HPLC.  Alternatively, levels of phosphorylated Akt could be measured, as a downstream kinase 
in PI3K-mediated signaling.  Additionally, the effectiveness of the butanol in inhibiting PA 
production could be assayed by confirming that this drug treatment alters Raf traffic, which has 
been previously determined to require this lipid. 
3.3.6. Live cell dynamics of KSR 
In order to visualize KSR traffic, green fluorescent protein (GFP) fusions of both the WT (Figure 
16A) and MT (Figure 16B) were transfected into HIRcB cells, and imaged by confocal 
microscopy.  Examination of the subcellular distribution of KSR reveals it to have a diffuse 
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 cytosolic distribution, although a significant portion is found localized to membrane ruffle 
structures, both in unstimulated and stimulated cells.  These ruffles assemble and are internalized 
rapidly, as seen by comparing the images where indicated with arrows Pre-incubating the cells 
with the PA-synthesis inhibitor 1-propanol or the PI3K inhibitors wortmannin and LY294002 
prior to stimulation had no effect on traffic of either the WT or the MT KSR protein.  Thus, the 
live cell imaging supports the biochemical data indicating KSR traffic is both lipid- and agonist-
independent. 
Live cell dynamics of Ras/ERK family members in these cells have been well characterized by 
our lab.  Ras, for example, can be easily visualized at the plasma membrane in quiescent cells.  
Upon stimulation of the cells with insulin, there is a rapid internalization of Ras in punctuate 
structures.  This traffic is strictly agonist dependent [11].  Raf-1 traffic has been explored using 
confocal microscopy as well.  By focusing on the region of the cell just above the level of the 
coverslip, it is possible to visualize the surge in Raf-1-GFP membrane association following cell 
stimulation [10].  Characterization of the endosomes isolated in response to insulin stimulation 
also show a definitive time course for association of Ras, Raf, MEK, and ERK.  Both Ras and 
Raf association peak between 5 and 15 minutes following stimulation.  MEK and ERK 
association is also transient; maximum levels of ERK and MEK are detectable at approximately 
15 minutes of stimulation [15].  Thus, the purpose KSR constitutive association with both the 
plasma membrane and the endosomal compartment in these cells remains elusive. 
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Figure 16 – Live cell dynamics of GFP-WT and GFP-MT KSR 
 
HIRcB cells were transfected with GFP fusions of the WT and MT KSR using the non-
fluorescent transfection reagent Superfect.  Each paired set of images reflects the same cell, two 
minutes apart.  Points of interest are highlighted with arrows. 
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4. Concluding Remarks and Future Work 
In recent years, the field of signal transduction has seen a surge of interest in scaffolding 
proteins.  Indeed, scaffolding provides an elegant mechanism by which to enhance the specificity 
and efficiency of signaling.  Facilitation of signal protein interaction, concentration of kinases in 
a specific subcellular location, and sequestration of signaling components to prevent aberrant 
activation are all functions that have attributed to this class of proteins. 
The work presented in this thesis has focused on the Kinase Suppressor of Ras, a scaffolding 
molecule for the Ras/ERK signaling cascade.  Although it is widely accepted that KSR scaffolds 
MEK and ERK and enhances their activation, very little is actually known about the regulation 
of this protein.  The purpose of my thesis was to investigate the role of the PABR in KSR traffic 
and function.   
The data presented here suggest a direct KSR-lipid interaction.  Membrane association of KSR is 
essential for its function in facilitating ERK phosphorylation [62], but the underlying mechanism 
of this recruitment has not been determined. Based on sequence identity (28% identity, 46% 
similiarity) and in vivo functional studies, KSR is proposed to be similar in structure to Raf, and 
membrane binding of Raf depends upon interaction with PA.  Mutation of the Raf PBM 
generates a dominant negative protein, and ablates its ability to interact with the membrane [7].  
In vitro analysis of the same PBM mutation in the KSR PABR suggests possible reduced binding 
to PA.  Moreover, expression of the full-length KSR PBM mutant in HIRcB cells dominantly 
inhibited ERK phosphorylation.  Thus, it was quite surprising that neither the PABR mutation 
nor PA-synthesis inhibition altered KSR association with the membrane.   
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 What, then, is the mechanism underlying the dominant inhibition conferred by the PBM 
mutation?  In the case of Raf, the answer to this question is more straightforward.  Mutation of 
the PABR disables membrane association, preventing Raf interaction with Ras, and uncoupling 
the signal.  In the case of KSR, however, the PBM mutation does not seem to affect membrane 
association.  It has been previously reported by our lab that the components of the Ras/ERK 
signaling cascade assemble on the surface of early endosomes, and that these endocytic vesicles 
are enriched in PA [7, 15].  Neither MEK nor ERK possess a defined lipid binding domain, 
suggesting the involvement of a scaffolding protein in their endosomal recruitment.  KSR has 
been previously reported to interact with both MEK and ERK.  The data presented here support a 
model in which the PABR of KSR binds PA in vitro.  Further, KSR localizes to endosomes in 
vivo.  Thus, the simplest model to incorporate all data states that KSR is involved in the 
endosomal recruitment of MEK and ERK, and its scaffolding function allows it to properly 
present MEK to Raf-1 for activation.  Although the initial association of KSR with the 
membrane may not be mediated by PA, KSR’s maneuvering of MEK and ERK into close 
enough proximity with Raf-1 may require direct interaction with the lipid.  MT KSR therefore 
uncouples ERK and MEK phosphorylation by sequestering them away from PA- and 
cholesterol-rich subdomains where the upstream signaling components are located (Figure 17). 
Although the work presented here demonstrates the association of KSR with the membrane 
compartment, the model described above is predicated on the temporal and spatial colocalization 
of KSR and Raf.  The association of Raf with membranes is agonist dependent, but data 
presented in this thesis demonstrate that KSR traffic is constitutive.  Application of agonist may 
induce the redistribution of KSR among membrane compartments.  The membrane to which 
KSR associates in quiescent cells may lack Ras and Raf, resulting in an incomplete signaling 
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 unit.  Agonist dependent processes would then redistribute KSR to a compartment which does 
contain the remaining components of the cascade.  The binding of PA to the PABR of KSR 
could play a central role in this redistribution.  Immunoelectron microscopy would prove useful 
in addressing this question.  This technique would allow us to demonstrate concurrent 
association of KSR and Raf with the same vesicle compartment, and verify that they are in close 
proximity.   
There is another possible explanation for these effects.  Ku68, a loss of function mutation in C. 
elegans KSR [44], corresponds to an R615H mutation in mKSR-1.  This point mutation is 
located within the PBM.  The R615H mutant is reported to have a decreased affinity for MEK 
[54].  This arginine residue is located within the PBM, and is mutated to an alanine in MT KSR.  
Thus, the possibility that MT KSR simply has a decreased affinity for MEK cannot be ruled out2.  
However, it is important to note that the authors do not test the affinity of the R615H for MEK in 
vitro; they simply demonstrate that there is less MEK associated with this mutant in the context 
of an immunoprecipitation.  MEK affinity for MT KSR versus WT KSR could be determined 
using recombinant proteins in vitro, and subsequent pull-down of KSR and Western blotting for 
scaffolded components.  If MT KSR affinity for MEK is reduced, this does not necessarily 
preclude ERK binding.  There has been no determination of cooperativity in MEK and ERK 
association with KSR, although a C809Y mutation in the kinase domain abolishes both MEK 
and ERK association with the scaffold [54].  This, too, could be determined by in vitro binding 
analysis.  If MT KSR demonstrates reduced affinity for MEK, but retains binding to ERK, its 
dominant negative effects could be caused by sequestration of ERK from its upstream activators.  
                                                 
2 Unfortunately, attempts to determine if MT KSR retained the ability to bind MEK were unsuccessful; KSR-MEK 
complexes could not be detected in HIRcB cells.  The reason for this failure to co-immunopreciptate KSR with 
MEK or ERK is unclear. 
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 Additionally, crosslinking experiments would be useful in determining the effects of inhibiting 
PA synthesis on the association of KSR with its scaffolded components.   
It is feasible that PA binding may induce a conformational change of the protein.  Circular 
dichroism experiments conducted by our lab for both KSR and Raf-1 PABR have provided 
preliminary evidence suggesting that there may be a structural rearrangement upon addition of 
lipid.  The WT peptide alone appears to be predominantly (~70%) in a random coil 
conformation; however, addition of lipid induces a spectral change consistent with β-sheet 
formation.  The CD spectrum of the MT PABR peptide was consistent with an even larger 
unstructured component (90% random coil), and addition of lipid induced very small spectral 
changes.  From these data, we tentatively draw the following conclusions: mutations within the 
PBM induce a conformational change in the isolated PABR, and an intact PBM is required to 
observe a lipid-induced reordering of the peptide.  A lipid-induced conformational change may 
either modulate binding of KSR for MEK and ERK, or change their relative spatial orientation.  
It would be particularly interesting to extend the studies of lipid effects on KSR alone to the 
investigation of the effects of lipids on KSR association with MEK and ERK.  This will again 
require in vitro experiments with recombinant proteins.   
Here we also report that MT KSR is an agonist-specific dominant negative, although the import 
of this finding has not been determined.  Inhibition of PLD2 in HIRcB cells results in a decrease 
in ERK activation and impedes Raf membrane association [10].  EGF does not activate PLD in 
these cells [100], indicating there may be an alternate mechanism for either PA synthesis (i.e. 
DAG kinase activity) or membrane recruitment of Ras/ERK proteins.  The concept of agonist 
specificity of scaffolds is not unprecedented in the literature, although very little is understood 
about how this may occur.  The recently identified MORG-1, for instance, is implicated in ERK 
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 phosphorylation in response to serum, but not EGF [38].  MP1 mediates MEK phosphorylation 
during cell adhesion and spreading, but has no role in the PDGF response [37].  MP1 is 
particularly interesting, in that it serves to tether MEK1 and ERK1 specifically to lysosomes.  
Changing MP1 localization by artificially targeting it to the plasma membrane inhibits ERK 
activation [34].  This data indicates that impedance of scaffold interaction with the proper 
subcellular compartment can uncouple signaling, consistent with the model described above for 
KSR. 
The KSR PABR is essential for its proper fuction in the Ras/ERK pathway.  Mutation of this 
region may eliminate lipid binding in vitro, and produces a dominant negative scaffold in vivo. 
Mutation of the PABR is not sufficient to prevent the association of the full-length protein with 
the plasma membrane, nor the endocytic compartment.  Taken together, these data indicate that, 
despite their sequence similarity, the traffic of KSR and Raf-1 is mediated by distinct 
mechanisms.  As mentioned above, immunoelectron microscopy would be useful in determining 
the colocalization of Raf and KSR, to verify that they are in fact localized to the same vesicular 
compartment.  It has been shown that the PABR of Raf-1 is sufficient to target GFP to the 
membrane and endosomal compartment.  Mutation of the PBM results in a cytosolic distribution 
of this fusion protein [7].  This experiment could be expanded to include a KSR PABR-GFP 
fusion protein, to explore any differences in traffic of the two different domains.  Another 
imaging technique that may prove useful is fluorescence resonance energy transfer (FRET).  
FRET between fluorophore fusion KSR and Raf-1 proteins could be used to determine not only 
that the proteins are in the same compartment, but that they are in close proximity to each other.  
Furthermore, live cell microscopy of cells expressing labeled KSR and Raf-1 would allow us to 
resolve any temporal differences in traffic of these two proteins.  It would be expected, if the 
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 model proposed in this thesis is correct, that WT KSR and Raf-1 would demonstrate energy 
transfer, but no FRET would be detectable with the PABR mutant.   
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Figure 17 – A model for WT and MT KSR in HIRcB cells  
 
See text for a detailed explanation.  Briefly, MT KSR (red) acts as a dominant negative by 
sequestering ERK and MEK away from PA-rich regions of the endosome.  Only KSR possessing 
an intact PABR PBM (WT KSR, blue) can successfully couple the signaling pathway by 
associating with PA-enriched microenvironments. 
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APPENDIX A 
Abbreviations 
 
CRD  cysteine rich domain 
DAG  diacylglycerol 
DHPA  dihexanoyl phosphatidic acid 
DOPA  dioleoyl phosphatidic acid 
DOPS  dioleoyl phosphatidyl serine 
DPPA  dipalmitoyl phosphatidic acid 
EEA-1  early endosome antigen 1 
EGF  epidermal growth factor 
GFP  green fluorescent protein 
KSR  kinase suppressor of Ras 
MAPK  mitogen-activated protein kinase 
MEK  MAPK/ERK kinase 
MP1  MEK partner 1 
MT KSR KSR R615/618A 
MUV  multiple vulval phenotype 
PA  phosphatidic acid 
PABR  phosphatidic acid binding region 
PBM  poly-basic motif of the PABR 
PBS  phosphate buffered saline 
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 PC  phosphatidyl choline 
PDGF  platelet derived growth factor 
PI  phosphatidyl inositide 
PI3P  phosphatidyl inositide-3-phosphate 
PI3,4P  phosphatidyl inositide-3,4-phosphate 
PI3,5P  phosphatidyl inositide-3,5-phosphate 
PI4,5P  phosphatidyl inositide-4,5-phosphate 
PI3,4,5P  phosphatidyl inositide-3,4,5-phosphate 
POPA  palmitoyl oleoyl phosphatidic acid 
PS  phosphatidyl serine 
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